Department of Otolaryngology Head and Neck Surgery, Beijing Friendship Hospital, Capital Medical University, Xicheng District.
Department of General Surgery, General Hospital of Chinese People's Liberation Army, Beijing.
Int J Surg. 2023 Mar 1;109(3):429-437. doi: 10.1097/JS9.0000000000000266.
Routine prophylaxis for at-risk patients may reduce the occurrence of postoperative hypocalcemia but is not widely adopted due to a lack of evidence on the efficacy of available prophylactic strategies. In this study, we compared the relative efficacy of prophylactic strategies for postthyroidectomy hypocalcemia with a systematic review and network meta-analysis.
PubMed, Embase, and Cochrane Library were searched, covering the period from 1980 to May 2022, for randomized controlled trials (RCTs) comparing calcium, vitamin D 3 , activated vitamin D 3 , teriparatide, steroids, and magnesium with placebo or each other in patients receiving total or completion thyroidectomy. Involved RCTs reporting symptomatic or biochemical hypocalcemia. The primary outcome was symptomatic hypocalcemia, defined as circumoral tingling, and Chvostek and Trousseau signs. The secondary outcome was biochemical hypocalcemia. Risk of bias was assessed using the Cochrane risk of bias assessment tool for randomized trials. Pooled estimates were calculated using a random-effects inverse-variance weighting model. The network meta-analysis was performed under the frequentist framework. This meta-analysis was registered on the PROSPERO (International prospective register of systematic reviews) (CRD42022299982).
Twenty-seven RCTs comprising 3382 patients are included. Prophylactic strategies of teriparatide, oral calcium plus vitamin D 3 , and oral calcium plus activated vitamin D 3 are superior to placebo in reducing symptomatic hypocalcemia. Teriparatide emerged as the most effective strategy for symptomatic hypocalcemia [relative risk (RR): 0.18; 95% CI: 0.03-0.98], followed by oral calcium plus activated vitamin D 3 (RR: 0.42; 95% CI: 0.25-0.73) and oral calcium plus vitamin D 3 (RR: 0.43; 95% CI: 0.26-0.71). Evidence on monotherapy with either oral calcium or vitamin D 3 in reducing symptomatic hypocalcemia is insufficient. Intravenous calcium and oral calcium are effective in reducing biochemical hypocalcemia.
This network meta-analysis provides information on the relative efficacy of current prophylactic strategies for postthyroidectomy hypocalcemia. Teriparatide performed better than other interventions and would seem appropriate for deployment among high-risk populations.
对于高危患者,常规预防可能会降低术后低钙血症的发生,但由于缺乏现有预防策略疗效的证据,因此并未广泛采用。在这项研究中,我们通过系统评价和网络荟萃分析比较了甲状旁腺手术后低钙血症的预防策略的相对疗效。
检索了 1980 年至 2022 年 5 月期间的 PubMed、Embase 和 Cochrane Library,以比较接受甲状腺全切除术或近全切除术的患者中,钙、维生素 D3、活性维生素 D3、特立帕肽、类固醇和镁与安慰剂或彼此之间在预防甲状旁腺手术后低钙血症方面的随机对照试验(RCT)。涉及的 RCT 报告了症状性或生化低钙血症。主要结局是症状性低钙血症,定义为口周刺痛和 Chvostek 和 Trousseau 征。次要结局是生化低钙血症。使用 Cochrane 随机对照试验风险偏倚评估工具评估风险偏倚。使用随机效应逆方差加权模型计算汇总估计值。网络荟萃分析是在经典框架下进行的。该荟萃分析已在 PROSPERO(国际系统评价前瞻性注册库)(CRD42022299982)上注册。
纳入了 27 项 RCT,共 3382 名患者。特立帕肽、口服钙加维生素 D3 和口服钙加活性维生素 D3 预防策略在降低症状性低钙血症方面优于安慰剂。特立帕肽在降低症状性低钙血症方面是最有效的策略[相对风险(RR):0.18;95%置信区间:0.03-0.98],其次是口服钙加活性维生素 D3(RR:0.42;95%置信区间:0.25-0.73)和口服钙加维生素 D3(RR:0.43;95%置信区间:0.26-0.71)。关于单药口服钙或维生素 D3 降低症状性低钙血症的证据不足。静脉注射钙和口服钙均可有效降低生化低钙血症。
这项网络荟萃分析提供了关于目前甲状旁腺手术后低钙血症预防策略相对疗效的信息。特立帕肽的效果优于其他干预措施,因此似乎适合高危人群使用。